Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Arch Pediatr ; 23(11): 1191-1200, 2016 Nov.
Article in French | MEDLINE | ID: mdl-27743765

ABSTRACT

These guidelines are intended to assist physicians in the care of children with chronic kidney disease (CKD), defined in children as in adults, regardless of its cause. Often silent for a long time, CKD can evolve to chronic renal failure or end-stage renal disease. Its management aims at slowing disease progression and treating CKD complications as soon as they appear. The different aspects of pediatric CKD care are addressed in these guidelines (screening, treatment, monitoring, diet, quality of life) as proposed by the French Society of Pediatric Nephrology. Highly specialized care provided in the hospital setting by pediatric nephrologists is not detailed.


Subject(s)
Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/therapy , Albuminuria/etiology , Albuminuria/therapy , Anemia/etiology , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/therapy , Cardiovascular Diseases/etiology , Cardiovascular Diseases/therapy , Child , Child Nutrition Disorders/etiology , Child Nutrition Disorders/therapy , Disease Management , Glomerular Filtration Rate , Hemoglobins/analysis , Humans , Mass Screening , Opportunistic Infections/prevention & control , Proteinuria/etiology , Proteinuria/therapy , Quality of Life , Reference Values , Renal Insufficiency, Chronic/complications , Vaccination
2.
Eur J Pediatr ; 174(1): 23-32, 2015 Jan.
Article in English | MEDLINE | ID: mdl-24953377

ABSTRACT

UNLABELLED: Renovascular hypertension accounts for 5-10 % of hypertension cases in children; there is currently no consensus on treatment. Here, we report on our clinical experience with this disease and outline the different pathways in which to investigate it. We report retrospectively on ten children diagnosed with renovascular hypertension at the University Hospital of Nantes from 2001 to 2012. The main findings were obtained by fortuitous screening of children aged 2 months to 14 years old with neurofibromatosis (n = 2) and fibromuscular dysplasia (n = 8). The hypertension was always severe yet asymptomatic. Lesions were complicated in nine out of ten cases and included bilateral, multiple, mid-aortic syndrome and aneurysm. Doppler ultrasound associated with computed tomography allowed for a precise diagnosis in seven out of ten cases. Where ambiguities persisted, they were highlighted by arteriography, the gold standard investigation. Medical treatment was insufficient, leading to invasive procedures in nine out of ten children: 2 nephrectomies, 2 autotransplantations, and 21 repetitive percutaneous transluminal angioplasties. After invasive procedures, blood pressure control improved in four cases and was resolved in three. CONCLUSION: Arteriography remains to be the gold standard technique for renovascular hypertension in children and can be combined with angioplasty when medical treatment is rendered obsolete. The role of computed tomography is controversial. Despite the heterogeneity of the children studied, we present a general medical and therapeutic management pathway for the treatment of this disease.


Subject(s)
Hypertension, Renovascular/diagnosis , Hypertension, Renovascular/therapy , Adolescent , Angiography/methods , Angioplasty , Child , Child, Preschool , Female , Fibromuscular Dysplasia/complications , Humans , Infant , Male , Neurofibromatosis 1/complications , Renin-Angiotensin System/physiology , Retrospective Studies , Tomography, X-Ray Computed/methods , Ultrasonography, Doppler
3.
Pediatr Transplant ; 17(6): E131-6, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23834525

ABSTRACT

Bortezomib has appeared recently as a potential active treatment for acute AMR for few years. We reported a patient who received two courses of bortezomib for the treatment of an acute AMR associated with de novo HLA DSA that occurred 18 months after renal transplantation because of non-compliance. Graft biopsy revealed features of acute humoral rejection with plasmocyte infiltration and C4d staining. Bortezomib was associated with corticosteroid pulses, IVIgs, and PP. Despite this rapid management, the patient lost his graft and carried on dialysis. Bortezomib therapy in addition to current therapy of AMR is not always effective in the treatment for late acute AMR in renal transplantation. We discuss on the place of such a treatment and other therapeutic strategies in this indication.


Subject(s)
Antibodies/chemistry , Boronic Acids/therapeutic use , Graft Rejection/drug therapy , Kidney Transplantation/methods , Polycystic Kidney, Autosomal Recessive/therapy , Pyrazines/therapeutic use , Adolescent , Adrenal Cortex Hormones/therapeutic use , Biopsy , Bortezomib , Complement C4b/chemistry , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/chemistry , Male , Patient Compliance , Peptide Fragments/chemistry , Protease Inhibitors/therapeutic use , Renal Dialysis/methods , Treatment Outcome
4.
Arch Pediatr ; 18(9): 955-61, 2011 Sep.
Article in French | MEDLINE | ID: mdl-21795028

ABSTRACT

PURPOSE: To compare two first febrile urinary tract infection (UTI) management protocols with regards to the diagnosis of high-grade vesicoureteral reflux (VUR) and cost. METHODS: This study compared two cohorts of children under 16 years of age, admitted for a first episode of febrile UTI. The first group (in 2005) was managed according to previous recommendations (IV treatment and cystography performed for all children under 3 years of age). The second group (in 2006) was managed according to age and procalcitonin level. High-grade VUR frequency, UTI recurrence, hospitalization rate, and cost were compared between the two cohorts. RESULTS: A total of 225 children were included in 2005 and 116 in 2006. High-grade VUR was found in 6.2 and 9.5% of the patients in 2005 and 2006, respectively (P=0.274). There was no statistically significant difference in the UTI recurrence rate between the two cohorts (5.3% in 2005 and 8.6% in 2006; P=0.237). The mean cost of an episode of febrile UTI was not significantly different in 2005 and 2006 (€2235 in 2005, €2256 in 2006; P=0.902), but was lower for children older than 6 months in 2006 (€1292 versus €1882 in 2005; P=0.0042). CONCLUSION: Our management protocol for a first febrile UTI episode in children based on procalcitonin levels seems to be suitable for the diagnosis of high-grade VUR. The hospitalization rate and the mean cost of management for children older than 6 months of age was significantly reduced in 2006. The management guidelines for a first occurrence of febrile UTI in children should be reconsidered.


Subject(s)
Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , Vesico-Ureteral Reflux/complications , Vesico-Ureteral Reflux/drug therapy , Adolescent , Anti-Bacterial Agents/therapeutic use , Biomarkers/urine , Calcitonin/urine , Calcitonin Gene-Related Peptide , Child , Child, Preschool , Cohort Studies , Female , Fever/microbiology , France , Humans , Infant , Inpatients , Length of Stay/economics , Male , Practice Guidelines as Topic , Predictive Value of Tests , Protein Precursors/urine , Sensitivity and Specificity , Treatment Outcome , Urinary Tract Infections/diagnosis , Urinary Tract Infections/economics , Urinary Tract Infections/urine , Vesico-Ureteral Reflux/diagnosis , Vesico-Ureteral Reflux/economics , Vesico-Ureteral Reflux/urine
5.
Pediatr Transplant ; 13(6): 725-30, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19691564

ABSTRACT

OBJECTIVE AND METHODS: To assess patient survival in pediatric renal transplantation, we retrospectively reviewed 573 transplants in 553 patients, registered from 1995 to 2005. RESULTS: Mean age at transplantation was 9.9 years. Patient survival at 1, 5 and 10 years was respectively 99%, 97% and 96%. Death occurred at a median time of 2.6 years after transplantation. Long-term patient survival was significantly lower in recipients younger than 5 years old. Seventeen patients (3.1%) died. Two deaths occurred while under maintenance dialysis. Among the remaining patients, the two main causes of death were infections (33%) and malignancies (27%). Interestingly, initial disease-related complications were a major cause of death (34%). CONCLUSION: A low mortality rate was observed, with the majority of deaths due to malignancies and infections, and with a notable participation of complications related to the initial disease. No impact of cardiovascular disease was noted with the given follow-up period. Improvements in managing immunosuppression may contribute to reducing mortality in pediatric renal transplantation.


Subject(s)
Graft Rejection/mortality , Kidney Diseases/mortality , Kidney Diseases/therapy , Kidney Transplantation/methods , Child , Child, Preschool , Databases, Factual , France , Humans , Immunosuppressive Agents/therapeutic use , Kidney Diseases/surgery , Kidney Transplantation/adverse effects , Registries , Renal Dialysis , Retrospective Studies , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...